

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

February 10, 2015

Safe Orthopaedics Mr. Pierre Dumouchel Quality Affairs & Regulatory Affairs Parc des Bellevues – Allée R. Luxembourg – Bat. Californie 95610 Eragny sur Oise FRANCE

Re: K150092

Trade/Device Name: SteriSpineTM PS Pedicle Screw

Regulation Number: 21 CFR 888.3070

Regulation Name: Pedicle screw spinal system

Regulatory Class: Class III

Product Code: NKB, MNI, MNH, KWP

Dated: January 9, 2015 Received: January 16, 2015

Dear Mr. Dumouchel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

FORM FDA 3881 (1/14) Page 1 of 1 PSC Publishing Services (60) 443-6740 EF

Special 510k STERISPINE® PS



510(k) SUMMARY

510k	Special 510k
Basis for submission	Addition of a Percutaneous Ancillary Kit to the previously cleared
	Sterispine [™] PS range of products
Submitted by	Safe Orthopaedics
	Parc des Bellevues
	Allée R. Luxembourg - Le Californie
	95610 Eragny sur Oise – FRANCE
	Phone: +33 (0) 1 34 21 50 00
Contacts	Pierre DUMOUCHEL - Quality affairs & Regulatory affairs Director
	p.dumouchel@safeorthopaedics.com
	Regulatory contact : Isabelle DRUBAIX (Idée Consulting)
	idee-consulting@nordnet.fr
Date Prepared	January 9 th 2015
Common Name	Pedicle screw spinal system
Trade Name	Sterispine [™] PS Pedicle Screw
Classification Name	Pedicle screw spinal system
Class	III
Product Code	NKB, MNI, MNH, KWP
CFR section	888.3070
Device panel	Orthopedic
Legally marketed	Sterispine [™] PS Pedicle Screw K112453 manufactured by Safe
predicate devices	Orthopaedics (Primary Predicate)
Indications for use	The SteriSpine [™] PS system is intended to provide immobilization and
	stabilization of spinal segments in skeletally mature patients as an
	adjunct to fusion. SteriSpine [™] PS System is intended for posterior, non-
	cervical pedicle and non-pedicle fixation for the following indications:
	degenerative disc disease (DDD) (defined as back pain of discogenic
	origin with degeneration of the disc confirmed by history and
	radiographic studies); spondylolisthesis; trauma (i.e., fracture or
	dislocation); spinal stenosis; tumor; pseudoarthrosis; and failed previous
	fusion.

	The cleared range of SteriSpine TM PS system include multiaxial screws and
	cannulated multiaxial screws with or without extended head (ø5.5, 6.5
	and 7.5mm, lengths from 25 to 60 mm) and straight and prebent rods (ø
	5.5, 6.5 and 7.5mm, lengths from 30 to 380 mm). Components of
Description of the	SteriSpine [™] PS system are made of Titanium Ta6V Eli grade conforming
device & Technological	to ASTM F136. The SteriSpine™PS range of products is supplied sterile
Characteristics	with a sterile single-use set of surgical instruments. The Percutaneous
	Ancillary Kit added within this submission include (trocar needle, dilators,
	rod measurer, protection sleeve, funnel body, funnel shaft and funnel
	impactor). These instruments are supplied as a sterile single-use set to
	be used with the previously cleared Ancillary Kits.
Discussion of Testing	No testing has been performed for the added components.
	The extended range of SteriSpine [™] PS system is substantially equivalent
	to its predicate device SteriSpine [™] PS system (K112453) in terms of
Conclusion	intended use, material, design, mechanical properties and function.
	Verification Activity and Validation Activity demonstrate that components
	added to SteriSpine $^{^{\mathrm{TM}}}$ PS system are substantially equivalent to predicates.